BPC-157 + TB-500 Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 4 to 8 weeks on, with 2 to 4 weeks off; severe or post-surgical cases may extend to 12 weeks under medical supervision
• Frequency: BPC-157 daily; TB-500 two to three times per week on non-consecutive days
• Common delivery routes: Subcutaneous injection for both peptides (BPC-157 near the injury site for localized goals; TB-500 systemic, injection location flexible)
• Key timing notes: BPC-157 requires daily consistency due to its short plasma half-life; TB-500 benefits from non-consecutive dosing days to maintain steady systemic exposure

Who This Protocol Is For

The BPC-157 + TB-500 combination, sometimes called the Wolverine Stack in peptide communities, is most commonly run by people dealing with musculoskeletal injuries that have not responded well to standard rest-and-recovery approaches. Tendon injuries, rotator cuff issues, chronic tendinitis, plantar fasciitis, post-surgical repair, and gut lining repair are the situations that come up most consistently in user logs and practitioner protocols.

The two peptides serve different but complementary roles. BPC-157 works primarily at the local level, driving repair signaling at and near the injection site, while TB-500 works systemically, supporting broader cellular regeneration and inhibiting the scar tissue formation that can limit full recovery. Because their mechanisms do not overlap completely, many people find the combination more useful than either peptide alone for complex or stubborn injuries.

Experience level matters here, but not in the way it does with performance compounds. Someone new to peptides can run this stack, but the protocol involves two separate reconstitutions, two separate injection sites, and a daily commitment for BPC-157. People who are comfortable with subcutaneous injection technique and methodical about their preparation tend to get more consistent results.

For gut-specific goals, BPC-157 alone has some use via oral or nasal routes and may be worth exploring as a separate single-peptide approach.

How Is a BPC-157 + TB-500 Cycle Structured?

A standard BPC-157 + TB-500 cycle has a clear arc: a front-loaded early phase where the body builds consistent peptide exposure, followed by a steady maintenance phase where the repair work compounds, and then a structured off-cycle break before any repeat round.

The first one to two weeks establish daily consistency with BPC-157 and get regular TB-500 administrations underway. By week two or three, most people have settled into a rhythm, and that is when the maintenance phase is fully underway. The full mechanics of each phase are covered in the Loading and Maintenance Phases section below.

Cycle length is determined primarily by the goal. Minor or acute injuries are often addressed in two to four weeks. The most common protocol range for moderate injuries and tendinitis is four to six weeks. Severe injuries, post-surgical recovery, and neurological support situations run six to eight weeks, and some severe structural cases extend to twelve weeks under close medical supervision. The maximum continuous use cited across practitioner frameworks is ninety days, after which a washout period is required before restarting.

How Your Dose Is Determined

What moves a BPC-157 + TB-500 dose:

• Your goal: The injury type and severity are the primary drivers. Acute, localized injuries like a fresh tendinitis flare tend to run toward the lower end of the range for BPC-157. More severe structural injuries, post-surgical recovery, or chronic conditions trend toward the higher end. TB-500's weekly total also shifts by goal severity, with more demanding recovery situations calling for more frequent weekly administrations.
• Experience level: A first cycle typically starts conservatively to observe individual response before any adjustment. Someone with prior peptide experience and a clear read on how they respond has more context for where to land.
• Delivery route: For BPC-157, injecting near the injury drives more localized effect; abdominal injection is more systemic. TB-500's systemic mechanism means injection location is flexible without changing the dose.
• Individual response: Two people with the same injury type and severity can respond differently. Some notice meaningful change within the first week; others take three to four weeks to feel a clear shift. Individual variation is real and is one reason the dose needs to be personalized rather than fixed.

There is no single dose that fits everyone running this stack. BPC-157's short plasma half-life of under two hours means daily consistency matters more than the precise number, and the dose for each peptide shifts meaningfully depending on whether the goal is general maintenance, moderate recovery, or aggressive structural repair. Some protocols split the daily BPC-157 administration into two injections spaced several hours apart, which is explained fully in the timing section below.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your goal type, your injury severity, and whether you run BPC-157 once or twice daily and builds your BPC-157 + TB-500 protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take BPC-157 + TB-500?

BPC-157 and TB-500 run on fundamentally different schedules because they work differently inside the body, and understanding why matters for running the protocol correctly.

BPC-157 has a short plasma half-life of under two hours, meaning it clears the bloodstream quickly and lacks the intracellular persistence that TB-500 has. That is why BPC-157 requires daily dosing to maintain the repair signaling environment. Missing days with BPC-157 undermines the protocol in a way that is hard to recover from mid-cycle. Morning or evening administration are both fine; what matters most is consistency at roughly the same time each day. When BPC-157 is split into two daily administrations, doses are spaced at least four to six hours apart to maintain coverage across the day.

TB-500 behaves differently because it binds directly to actin monomers inside cells. That intracellular binding persists even after the peptide has cleared the bloodstream, which is why TB-500 is effective at a twice or three times per week frequency rather than daily. The key distinction from BPC-157 is this: TB-500's actin-binding activity continues well after blood levels drop, making less frequent administration viable. The most commonly run pattern is two injections per week on non-consecutive days, spaced roughly three to four days apart, which provides systemic coverage without daily administration.

Because the two peptides run on different frequencies, they run on separate tracks in the same overall protocol. BPC-157 gets a daily injection; TB-500 gets its own injection two or three times that week, at a separate site. The two are never mixed in the same vial or the same syringe, which is covered in the mistakes section below.

Loading and Maintenance Phases

This combination does use a loading concept, but it is worth being precise about what that means. The loading phase for BPC-157 + TB-500 is not a higher dose in the first week or two. The dose stays consistent from day one through the end of the cycle. The loading phase is simply the period of establishing consistent daily exposure for BPC-157 and getting the TB-500 schedule underway, allowing the repair signaling environment to build before results become noticeable.

The loading phase spans roughly the first one to two weeks. During this window the body adjusts to the new signaling environment, early side effects are most likely to appear, and the tissue environment is being prepared for the work ahead. Expecting dramatic early results here sets up frustration. The first two weeks are the foundation being laid.

The maintenance phase runs from approximately week two or three through the end of the cycle. The dose does not change, but the cumulative effect of consistent daily BPC-157 and twice or three times weekly TB-500 builds. This is where the tissue repair, inflammation reduction, and structural improvements that the stack is run for tend to become noticeable. Running the cycle to its planned endpoint, rather than stopping early when the first two weeks feel subtle, is one of the more important protocol disciplines.

Off-Cycle Considerations

Breaks from this combination are standard and important. Both peptides stimulate angiogenesis (the growth of new blood vessels) and cell proliferation, and structured off-cycle periods exist to prevent receptor desensitization and allow the body to consolidate the repair work initiated during the active phase.

The most widely run framework is two to four weeks off after a standard four to eight week cycle. A more conservative approach uses a four-week break after eight weeks on. For shorter thirty-day cycles, at least fifteen days off is the minimum cited in practitioner protocols. For the maximum continuous use scenario of ninety days, a full thirty-day washout is required before any repeat round.

The off-cycle period is not passive. Much of the structural healing and scar tissue remodeling that TB-500 initiates continues to progress after dosing stops, consistent with the intracellular persistence of its actin-binding mechanism. Users who track their recovery frequently report continued improvement in the first two to four weeks off cycle. Patience during this window matters as much as consistency during the active phase.

Neither BPC-157 nor TB-500 is FDA-approved for human use, and both are banned under WADA's S0 Unapproved Substances category, which covers use both in competition and during training. Competitive athletes subject to drug testing should not use either compound.

What to Expect Week by Week

• Week 1 to 2: Early side effects are most common in this window, including injection site irritation, mild fatigue, headaches, and what many users describe as a transient fight-or-flight feeling in the first few days. Some acute injuries, particularly fresh tendinitis, show early inflammation reduction and mild mobility improvement within the first three to seven days. For most people, the first two weeks are more about adjustment than obvious benefit.
• Week 3 to 4: The transition point for most users. Early side effects typically subside by the end of week two, and by week three therapeutic effects become more noticeable. Inflammation and pain continue declining, gut and digestion improvements are commonly reported around the two-week mark for gut-focused protocols, and workout recovery begins to feel meaningfully different for training-focused users.
• Week 5 to 8: The primary benefit window for most goals. The most consistent milestone across user logs is around day thirty-five, roughly week five, which users commonly describe as when the full effects of the stack are most clearly felt. Plantar fasciitis users commonly report near-elimination of pain by week six. Muscle and tendon trigger points that were painful earlier in the cycle are frequently described as resolved by weeks four to five.
• Beyond 8 weeks: For severe structural injuries such as a torn meniscus, protocols extend to twelve weeks. In some reported cases, users who completed twelve-week cycles for this level of injury described MRI findings showing structural improvements, including resolution of associated fluid buildup and near-absent pain at the end of the cycle.

These are commonly reported ranges drawn from real-world user data and practitioner protocols, not guarantees. Individual results vary by injury type, severity, injection consistency, and individual biology. What a well-run cycle commonly looks like when it goes right: someone dealing with chronic tendinitis that had not responded to months of physical therapy finds that by weeks four to six, the daily pain limiting their training is substantially reduced, mobility has returned, and the inflammation present at the start has cleared. That steady, cumulative progression built on consistent daily dosing is the realistic arc most users report when the protocol is followed correctly.

Common Protocol Mistakes

Mixing both peptides in one vial. BPC-157 and TB-500 have different pH profiles, and combining them in a single vial or syringe degrades the effectiveness of both. They must be reconstituted separately, drawn into separate syringes, and injected at separate sites. This is the most consequential preparation mistake in the stack and is common among people who assume a simpler preparation is equivalent.

Vortexing TB-500 during reconstitution. TB-500 is fragile during preparation. Shaking the vial or using a vortex mixer causes foaming and can denature the peptide, rendering it ineffective. The correct technique is to gently swirl or roll the vial between the palms and let it sit until fully dissolved. Injecting the solvent down the inner wall of the vial rather than directly onto the powder also reduces foaming.

Skipping BPC-157 daily doses. The sub-two-hour plasma half-life of BPC-157 means the repair signaling environment depends on daily consistency. Skipping two or three days in a row effectively interrupts the cycle. People who miss doses regularly and still run a full calendar cycle often report underwhelming results and assume the stack did not work.

Stopping the cycle in the first two weeks. Early side effects, particularly the transient fight-or-flight sensation and fatigue some users experience in week one, lead some people to stop before the loading phase has been completed. Stopping at this point means the maintenance phase and the bulk of the therapeutic benefit never happen. Most early side effects resolve by day fourteen.

Setting unrealistic timelines. Expecting dramatic change by day seven leads to abandoning a protocol that would have worked by week four or five. Chronic and structural injuries take longer than acute ones, and the full effect of TB-500's anti-fibrotic mechanism builds over weeks, not days.

Sourcing from unverifiable suppliers. Unregulated peptide sources carry real contamination risk: heavy metals and bacterial byproducts capable of causing serious infection have been found in samples from outside pharmaceutical supply chains. The risk applies to any compound administered subcutaneously. Verifiable manufacturing standards, independent third-party testing, and clear chain of custody are the minimum bar worth applying here.

Frequently Asked Questions

How long is a typical BPC-157 + TB-500 cycle?

Most protocols run four to eight weeks for moderate injuries and tendinitis, which is the most common use case. Acute minor injuries may be addressed in two to four weeks, while severe structural injuries and post-surgical recovery are run at up to twelve weeks under medical supervision. The exact cycle length for your situation is personalized in the MyPeptidePal Protocol Creator.

How often do you take BPC-157 + TB-500?

BPC-157 is taken daily throughout the cycle because its short plasma half-life requires daily consistency to maintain the repair signaling environment. TB-500 is taken two to three times per week on non-consecutive days, a pattern that works because its intracellular actin binding persists well beyond the peptide's clearance from the bloodstream.

Does the BPC-157 + TB-500 stack need a loading phase?

Yes, in the sense that the first one to two weeks represent a priming period where the body builds consistent peptide exposure, but the dose does not increase during this phase. The loading phase is about establishing daily rhythm and allowing the repair mechanisms to get underway, not about a higher number up front.

Do you need to cycle off BPC-157 + TB-500?

Yes. A structured break of two to four weeks is standard after a four to eight week cycle, and a thirty-day washout is required after any cycle approaching ninety days. The break allows the body to consolidate the repair work initiated during the active cycle and prevents the receptor desensitization that can develop with continuous long-term use.

Can BPC-157 be taken orally instead of injecting?

BPC-157 has some use via oral administration for gut-specific goals, where local action in the GI tract is the target. For musculoskeletal and systemic repair goals, subcutaneous injection is the standard route. TB-500 is not well-suited for oral use and is typically administered subcutaneously for any protocol goal.

Why can BPC-157 and TB-500 not be mixed in the same vial?

The two peptides have different pH profiles that are not compatible in solution. Combining them in one vial creates a mismatch that degrades the effectiveness of both compounds. They must always be reconstituted in separate vials, drawn into separate syringes, and injected at separate sites, even if the injections happen in the same session.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for BPC-157 + TB-500 in one place.